Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent A Fischetti

Showing results (41-50 of 138) with videos related to

Pageof 14
Sort By:
Journal of Bacteriology|July 30, 2013
Identification of a ligand on the Wip1 bacteriophage highly specific for a receptor on Bacillus anthracisSherry Kan, Nadine Fornelos, Raymond Schuch, et al.
Journal of Bacteriology|July 3, 2004
Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faeciumPauline Yoong, Raymond Schuch, Daniel Nelson, et al.
Frontiers in Cellular and Infection Microbiology|February 10, 2017
Oral Multiple Sclerosis Drugs Inhibit the <i>In vitro</i> Growth of Epsilon Toxin Producing Gut Bacterium, <i>Clostridium perfringens</i>Kareem R Rumah, Timothy K Vartanian, Vincent A Fischetti
International Journal of Food Microbiology|January 26, 2021
Decontamination of Escherichia coli O157:H7 on fresh Romaine lettuce using a novel bacteriophage lysinSiyue Xu, Edmondo Campisi, Jinquan Li, et al.
Frontiers in Microbiology|April 4, 2022
PaP1, a Broad-Spectrum Lysin-Derived Cationic Peptide to Treat Polymicrobial Skin InfectionsRyan D Heselpoth, Chad W Euler, Vincent A Fischetti
Antimicrobial Agents and Chemotherapy|November 12, 2025
Second-generation lysocins as therapeutics for treating <i>Pseudomonas aeruginosa</i> infectionsRyan D Heselpoth, Chad W Euler, Vincent A Fischetti
Antimicrobial Agents and Chemotherapy|September 23, 2015
Using a Novel Lysin To Help Control Clostridium difficile InfectionsQiong Wang, Chad W Euler, Aurelia Delaune, et al.
Plos One|October 23, 2013
Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the diseaseKareem Rashid Rumah, Jennifer Linden, Vincent A Fischetti, et al.
Journal of Medical Microbiology|July 2, 2013
Lysins: the arrival of pathogen-directed anti-infectivesMina Pastagia, Raymond Schuch, Vincent A Fischetti, et al.
The Journal of Infectious Diseases|May 13, 2008
Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitisDenis Grandgirard, Jutta M Loeffler, Vincent A Fischetti, et al.
Pageof 14

Showing results (41-50 of 138) with videos related to

Sort By:
Pageof 14
Journal of Bacteriology|July 30, 2013
Identification of a ligand on the Wip1 bacteriophage highly specific for a receptor on Bacillus anthracisSherry Kan, Nadine Fornelos, Raymond Schuch, et al.
Journal of Bacteriology|July 3, 2004
Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faeciumPauline Yoong, Raymond Schuch, Daniel Nelson, et al.
Frontiers in Cellular and Infection Microbiology|February 10, 2017
Oral Multiple Sclerosis Drugs Inhibit the <i>In vitro</i> Growth of Epsilon Toxin Producing Gut Bacterium, <i>Clostridium perfringens</i>Kareem R Rumah, Timothy K Vartanian, Vincent A Fischetti
International Journal of Food Microbiology|January 26, 2021
Decontamination of Escherichia coli O157:H7 on fresh Romaine lettuce using a novel bacteriophage lysinSiyue Xu, Edmondo Campisi, Jinquan Li, et al.
Frontiers in Microbiology|April 4, 2022
PaP1, a Broad-Spectrum Lysin-Derived Cationic Peptide to Treat Polymicrobial Skin InfectionsRyan D Heselpoth, Chad W Euler, Vincent A Fischetti
Antimicrobial Agents and Chemotherapy|November 12, 2025
Second-generation lysocins as therapeutics for treating <i>Pseudomonas aeruginosa</i> infectionsRyan D Heselpoth, Chad W Euler, Vincent A Fischetti
Antimicrobial Agents and Chemotherapy|September 23, 2015
Using a Novel Lysin To Help Control Clostridium difficile InfectionsQiong Wang, Chad W Euler, Aurelia Delaune, et al.
Plos One|October 23, 2013
Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the diseaseKareem Rashid Rumah, Jennifer Linden, Vincent A Fischetti, et al.
Journal of Medical Microbiology|July 2, 2013
Lysins: the arrival of pathogen-directed anti-infectivesMina Pastagia, Raymond Schuch, Vincent A Fischetti, et al.
The Journal of Infectious Diseases|May 13, 2008
Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitisDenis Grandgirard, Jutta M Loeffler, Vincent A Fischetti, et al.
Pageof 14